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A modular synthetic route to size-defined immunogenic 
Haemophilus influenzae b antigens is key to the identification of 
an octasaccharide lead vaccine candidate  
J. Y. Baek,a A. Geissner,a,b D. C. K. Rathwell,a,b D. Meierhofer,c C. L. Pereiraa,d,* and P. H. 
Seebergera,b,* 
The first glycoconjugate vaccine using isolated glycans was licensed to protect children from Haemophilus influenzae 
serotype b (Hib) infections. Subsequently, the first semisynthetic glycoconjugate vaccine using a mixture of antigens derived 
by polymerization targeted the same pathogen. Still, a detailed understanding concerning the correlation between 
oligosaccharide chain length and the immune response towards the polyribosyl-ribitol-phosphate (PRP) capsular 
polysaccharide that surrounds Hib remains elusive. The design of semisynthetic and synthetic Hib vaccines critically depends 
on the identification of the minimally protective epitope. Here, we demonstrate that an octasaccharide antigen containing 
four repeating disaccharide units resembles PRP polysaccharide in terms of immunogenicity and recognition by anti-Hib 
antibodies. Key to this discovery was the development of a modular synthesis that enabled access to oligosaccharides up to 
decamers. Glycan arrays containing the synthetic oligosaccharides were used to analyze anti-PRP sera for antibodies. 
Conjugates of the synthetic antigens and the carrier protein CRM197, which is used in licensed vaccines, were employed in 
immunization studies in rabbits. 
Introduction 
Haemophilus influenzae is a major cause of bacterial respiratory 
tract infections that can lead to severe diseases such as 
pneumonia, sepsis, and meningitis.1 While unencapsulated 
clones (nontypable H. influenzae) often cause local infections 
like otitis media or sinusitis, invasive disease is usually caused 
by H. influenzae expressing an antiopsonic polysaccharide 
capsule.2 Serotype b (Hib) is coated with a capsular 
polysaccharide (CPS) made up of polyribosyl-ribitol-phosphate 
(PRP) repeating units (RU) (Figure 1) and possesses the highest 
invasive potential among encapsulated H. influenzae; thus, it is 
a major health concern, especially for children.3  
This bacterium became the first pathogen for which a 
glycoconjugate vaccine was licensed.4 These glycoconjugate 
vaccines are produced from PRP that is isolated from bacterial 
fermentation, often size reduced, and subsequently chemically 
coupled to a carrier protein that induces a T cell-dependent immune response.
5 Routine vaccination in many countries has 
led to significant declines in bacterial burdens.6 
PRP is an interesting target for carbohydrate synthesis 
because of both its biological importance and the synthetic 
challenge inherent in generating longer oligosaccharides to 
serve as Hib vaccine antigens.7–10 Chemical synthesis provides a 
means to access chemically well-defined carbohydrate antigens 
without the danger of contamination from a pathogen 
culture.11 In the case of Hib, several methods have been used to 
obtain synthetic PRP (sPRP) oligosaccharides. For example, 
Just’s group synthesized short fragments of Hib PRP as trimers 
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Figure 1. Structure of the Hib CPS RU. 
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and pentamers by means of solution and solid phase 
approaches.12–15 Immunogenicity studies on semisynthetic 
glycoconjugates10,16 resulted in the first approved 
glycoconjugate vaccine in which the oligosaccharide hapten had 
been accessed by chemical synthesis.17 This vaccine, an sPRP-
tetanus toxoid (TT) conjugate referred to as Quimi-Hib was 
developed in Cuba and is now in routine use there and in several 
other countries.18 
Though clinically effective, the oligosaccharide component 
of Quimi-Hib represents a mixture of oligosaccharides, six to 
eight RUs on average, obtained by polycondensation.17 Size is 
considered to be an important factor in the efficacy of Hib 
glycoconjugate vaccines, but studies using oligo- and 
polysaccharides of varying length have yielded conflicting 
results.19 This finding can at least partially be attributed to the 
use of oligosaccharides obtained by chemically degraded PRP 
using different methods which do not yield defined 
oligosaccharides but rather mixtures of different lengths; thus, 
the lengths of the oligosaccharides that were tested varied 
considerably. Studies on length-defined sPRP have thus far only 
focused on a few shorter PRPs.10,20 Not only for Hib but for all 
other glycoconjugate vaccines it remains to be determined 
whether immunogenicity correlates with antigen length. This 
issue is of central importance for the development of 
semisynthetic or fully synthetic vaccines.21  
 To provide synthetic oligosaccharide antigens of defined 
length as tools to address the correlation of antigen length and 
immunogenicity, a solution-phase strategy using a disaccharide 
building block and elongation by means of H-phosphonate 
chemistry was chosen. The resulting glycans were immobilized 
on glycan arrays for antibody analysis and coupled to CRM197, 
an approved carrier protein for glycoconjugates,21,22 for 
subsequent immunizations. Immunogenicity studies in rabbits 
with semisynthetic sPRP-CRM197 glycoconjugates reveal that 
an octasaccharide containing four repeating disaccharide units 
induces antibody levels similar to those induced by longer 
oligosaccharides. 
Results and discussion 
Synthetic targets and strategy 
 
Retrosynthetic analysis of sPRP oligosaccharides 1-4 revealed a 
flexible strategy to access tetramer to decamer corresponding 
to structures that are present in the mixture of the Quimi-Hib™ 
vaccine (Figure 2). Dimer 10, with its orthogonal protecting 
groups, is the key intermediate for obtaining compounds 5-8, 
and it is in turn produced by coupling disaccharide 1417 with H-
phosphonate disaccharide 16. Disaccharides 13 and 16 can be 
obtained from 17, which is the product of β-stereoselective 
glycosylation between the suitably protected ribitol 1812,13,17 
and the commercially available peracetylated β-D-ribofuranose 
19. 
 
Synthesis of ribitol and ribose-ribitol building blocks 
Several syntheses of ribitol unit 18 have been reported,7–10,12–
15,17 but none of these methods is scalable. Ribitol derivative 18, 
required for the synthesis of sPRP, was prepared from the 
known dithioacetal building block 2112,13 that was obtained in 
turn from methyl 2,3-O-isopropylidene-β-D-ribofuranoside 20 
Figure 2. Retrosynthetic analysis of sPRP oligosaccharides 1-4 and respective sPRP-CRM197 glycoconjugates. 
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via a four step synthesis involving allylation at the 5-O-position, 
cleavage of isopropylidene, furanose ring opening and 
benzylation.12,13 Compound 21 was prepared at a larger scale 
with fewer purifications and improved yields (Supplementary 
Information). Although hydrolysis of the dithioacetal moiety of 
21 had been previously carried out using a mercury (II) reagent 
followed by reduction to 18,7–10,12,13 (Scheme 1) the removal of 
excess mercury (II) reagent was cumbersome at a large scale 
and only afforded the intermediate aldehyde in low yield and 
with poor reproducibility. Thus, to generate ribitol derivative 
18, dithioacetalribitol 21 was instead treated with NIS in 
aqueous acetone at -78 ˚C to yield the aldehyde, which was 
reduced using NaBH4, thereby circumventing toxic mercury 
based reagents. Protected ribitol 18 was readily synthesized at 
a 30 g scale from methyl 2,3-O-isopropylidene-β-D-
ribofuranoside with an overall yield of 43% over six steps. 
β-Stereoselective glycosylation of 19 with 18 using BF3·OEt2 
in dichloromethane (DCM) provided the disaccharide 
ribosylribitol 17 in 80% yield,17 which was deacetylated under 
Zemplén conditions to give disaccharide 22 (90% yield). To 
selectively protect the 2- and 5-O-positions of the ribose 
backbone, the permanent benzyl ether (Bn) protecting group 
was introduced via tin-mediated alkylation,17 providing 13 in 
50% yield in a single step (Scheme 1). Regioselective benzylation 
as well as the stereochemical configuration of key disaccharide 
13 was confirmed by NMR and these data agree with previous 
reports.17,23 Disaccharide 14 was then obtained by protection of 
the 3-hydroxyl of 13 as the levulinate ester 23 followed by 
deallylation using Pd(PPh3)4 and 1,3-dimethylbarbituric acid 
(DMBA).24 This deallylation method offers milder reaction 
conditions and shorter reaction times than other Pd-catalyzed 
methods. The synthesis of disaccharide 16 started with allyl 
deprotection of 13 to give diol 24, which was selectively 
protected at the 5-O-position of ribitol as a dimethoxytrityl 
(DMTr) ether leading to intermediate 15, which was in turn 
converted into H-phosphonate 16 by phosphitylation using 
PCl3–imidazole–Et3N.17 
 
Synthesis of key disaccharides 10, 11, and 12 
Coupling disaccharides 14 and 16 (Scheme 2) using pivaloyl 
chloride (PivCl) as activator, followed by in situ oxidation with 
iodine in pyridine/water, generated dimeric PRP fragment 10 in 
85% yield. The newly formed phosphodiester bond was 
confirmed by 31P NMR (δ -1.52 ppm). Fragment 10 served as 
central intermediate as it was converted into 11 by selective 
removal of the DMT group using trichloroacetic acid (TCA) in 
DCM, and, into 12 by removal of the levulinate ester using 
hydrazine-acetate followed by H-phosphonate formation. 
These dimeric PRP units became the crucial intermediates for 
the synthesis of tetrameric, hexameric, octameric, and 
decameric sPRP oligosaccharides. 
 
Synthesis of the tetrameric PRP oligosaccharide 1 
The synthesis of tetrameric PRP fragment 1 was accomplished 
using a (2+2) block approach involving coupling of dimer 11 and 
H-phosphonate 12 using PivCl as activator.7–10,12,13 To suppress 
several competing undesired side reactions such as O-
acylation17and P-acylation,25 a diluted solution of PivCl was 
added slowly to the reaction mixture of 11 and 12. Oxidation of 
the H-phosphonate intermediate of the tetrameric PRP 
fragment was accomplished using reported conditions17 and 
provided compound 5 in 85% yield as the triethylammonium 
salt (Scheme 3). The presence of the phosphodiester bridge in 5 
was confirmed by 31P NMR, which revealed three resonances at 
Scheme 1. Synthesis of ribitol unit 18 and disaccharides 13, 14, and 16. Reagents and conditions: (a) i. NIS, acetone, -78 ˚C; ii. NaBH4, EtOH, 0 ˚C, 43% (six steps from 20); (b) i. 
19, BF3·OEt2, DCM, -78 ˚C, 80%; ii. NaOMe, MeOH, RT, 90%; (c) Bu2SnO, toluene, reflux, 2 h, then BnCl, TBAI, NaH, DMF, 50 ˚C, 2 h, 50%; (d) LevOH, DMAP, DIC, DCM, RT, 93%; 
(e) Pd(PPh3)4, DMBA, MeOH, RT, 75% for 14, 75% for 24; (f) DMTrCl, DMAP, DCM, RT, 93%; (g) PCl3, Et3N, imidazole, DCM, 0 ˚C, 85%. NIS = N-iodosuccinimide, TBAI = 
tetrabutylammonium iodide, DIC =1,3-diisopropylcarbodiimide, DMAP = 4-dimethylaminopyridine, DMBA = 1,3-dimethylbarbituric acid. 
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δ 0.73, -0.05, and -0.47 ppm. Trityl cleavage from 5 followed by 
coupling with H-phosphonate linker 9 and subsequent oxidation 
gave the PRP intermediate 25. Delevulination led to 26 that was 
subjected to hydrogenolysis using a mixture of 
EtOAc/MeOH/50%AcOH(aq.) resulting in tetrameric PRP 1 as 
the sodium salt after purification (Scheme 3). 
The 1H NMR spectrum of the sodium form of sPRP 1 and that 
of the isolated Hib-PRP WHO standard are good agreement with 
one another (Figure 3).26 The spectra are similar for the 
backbone structure of ribose and ribitol and only display 
additional resonances in the case of sPRP because of the 
presence of the C5 alkyl linker. Furthermore, the spectrum for 
Scheme 2. Synthesis of dimeric PRP fragments 10, 11, and 12. Reagents and conditions: (a) 14, PivCl, pyridine, 0 ˚C, then I2, pyridine/H2O, RT, 85%; (b) TCA, 
DCM, RT, 90%; (c) i. hydrazine acetate, DCM, RT, 90%; ii. PCl3, Et3N, imidazole, DCM, 0 ˚C. PivCl = pivaloyl chloride, TCA = trichloroacetic acid. 
Scheme 3. Synthesis of the tetrameric PRP fragment 1 containing the aminopentyl linker. Reagents and conditions: (a) PivCl, pyridine, 0 ˚C, then I2, pyridine/H2O, RT, 
85%; (b) i. TCA, DCM, RT; ii. 9, PivCl, pyridine, 0 ˚C, then I2, pyridine/H2O, RT, 80% (over two steps); (c) hydrazine acetate, DCM, RT, 90% or 70% (one pot; three steps); 
(d) Pd/C, H2, EtOAc/MeOH/50%AcOH(aq.), 89%. PivCl = pivaloyl chloride, TCA = trichloroacetic acid. 
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sPRP 1 we recorded (Figure 3b) and the spectrum previously 
reported in the literature were found to be similar.9 
Alternatively, in order to improve PRP fragment elongation 
and reduce the number of purification steps, we carried out the 
three sequential reactions as a “one-pot” process of 
detritylation, coupling/oxidation, and delevulinilation to afford 
compound 26 in 70% yield over three steps (Scheme 3). This 
modified process was applied to the synthesis of Hib fragments 
6-8 (Scheme 4). 
 
Synthesis of the hexameric, octameric, and decameric sPRP 
oligosaccharides 2, 3, and 4 
Starting from tetrameric sPRP 5 and the iterative one-pot 
approach using dimeric intermediate 12 and H-phosphonate 
aminopentyl linker 9, the hexameric, octameric and decameric 
sPRP intermediates 27, 28 and 29, respectively, were obtained 
using the methods described above (Scheme 4). Finally, global 
deprotection of sPRP fragments 27, 28, and 29 under 
hydrogenolysis conditions using palladium and H2 (50 psi) in a 
mixture of EtOAc/MeOH/50%AcOH(aq.), followed by gel 
filtration over Sephadex LH-20 and cation-exchange (Dowex 
50WX4, Na+ form), gave the sPRP oligosaccharides 2, 3, and 4 in 
87%, 80%, and 79% yields, respectively (Scheme 4). The 
structural details were confirmed by NMR (Supplementary 
Information). 
 
Microarray analysis of PRP-directed polyclonal antibodies 
To ensure that the size-defined sPRP oligosaccharides are 
recognized by antibodies raised against natural Hib PRP, glycan 
array analyses were performed.27 The sPRP oligosaccharides 
containing the primary aminopentyl linker were immobilized on 
N-hydroxysuccinimide (NHS)-hydrogel glass slides (Figure S1) 
and the surface was subsequently incubated with one of two 
sera that contain Hib PRP-specific antibodies (Figure 4a and b). 
Concentration-dependent binding to all sPRP oligosaccharides 
was observed for pooled human sera used to calibrate Hib titer 
analyses as well as for a rabbit antiserum used for bacterial 
serotyping assays. Antibodies from the human serum also 
recognized the carrier protein CRM197 that was printed 
alongside the oligosaccharides, probably due the fact that 
diphtheria toxoid and CRM197 are routinely used as a vaccine 
antigen against diphtheria and as a carrier protein in approved 
glycoconjugate vaccines, respectively.21,28  
As the glycan arrays were probed with sera and not purified 
antibodies, an inhibition assay with the native Hib PRP was used 
to validate that antibodies binding to the sPRP oligosaccharides 
were indeed directed towards native Hib PRP. Although this 
specificity confirmation might not be strictly necessary for the 
rabbit hyperimmune serum as it is obtained under well-defined 
experimental conditions, it is known that humans develop 
antibodies against many glycan antigens over their lifetimes29 
that might cross-react with the sPRP oligosaccharides by 
chance. Therefore, different concentrations of WHO PRP 
standard were added to dilutions of both sera to capture Hib 
PRP-specific antibodies, thereby preventing them from binding 
to the sPRP oligosaccharides on the microarray surface and 
leading to signal suppression as a result of cross-reactivity. For 
both sera, concentration dependent signal suppression was 
seen that was complete at the highest employed PRP 
concentrations (Figure 4c and d). All antibodies that recognized 
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the sPRP oligosaccharides were directed against Hib PRP. 
Failure of the human serum to suppress binding to the CRM197 
spots confirmed specificity of the inhibition assay.  
While the cross-reactivity between the sPRP 
oligosaccharides and anti-PRP antibodies was readily 
established, determining the size of epitopes bound by the anti-
PRP antibodies in the two sera, was not possible. For the human 
serum, it was observed that the binding signals for dimer S4 
were reduced compared to the larger oligosaccharides (Figure 
4a), in agreement with an earlier immunization study that 
described comparatively poor reactivity of the dimer in rabbits: 
a dimer-TT conjugate induced significantly lower anti-PRP 
Scheme 4. Synthesis of elongated sPRP oligosaccharides 2, 3, and 4. Reagents and conditions: (a) i. TCA, DCM, RT; ii. 12, PivCl, pyridine, 0 ˚C, then 
I2, pyridine/H2O, RT, 85% for 6, 83% for 7, 80% for 8 (over two steps); (b) i. TCA, DCM, RT; ii. 9, PivCl, pyridine, 0 ˚C, then I2, pyridine/H2O, RT; iii. 
hydrazine acetate, DCM, RT, 74% for 27, 72% for 28, 72% for 29 (over three steps); (c) Pd/C, H2, EtOAc/MeOH/50%AcOH(aq.), 87% for 2, 80% for 
3, 79% for 4. PivCl = pivaloyl chloride, TCA = trichloroacetic acid. 
Figure 4. Glycan array binding analysis of anti-PRP antibodies to sPRP oligosaccharides 1-4. (a/b) Microarray slides printed with sPRP were incubated with a dilution 
series of a human reference serum (a) and rabbit anti-Hib antiserum (b) followed by a fluorescent secondary antibody, and fluorescence intensities for the 
synthetic length-defined glycans were determined. (c/d) To verify specificity of the analyzed antibodies, antibody binding was inhibited competitively by adding 
different concentrations of native PRP to human reference serum diluted 1:200 (c) or rabbit typing serum diluted 1:1000 (d). All values are the mean of eight spots 
from two replicate wells with error bars denoting the standard deviation (SD) 
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antibody levels than a trimer-TT conjugate.20 Binding signals to 
tetramer 1 were lower as well, albeit less pronounced. 
However, comparison of fluorescence intensities on glycan 
arrays is an imperfect measure of antibody binding strength 
since identical, repetitive epitopes result potentially in differing 
epitope densities. For example, if the same number of decamers 
and dimers were immobilized, the number of repeating units 
(potential binding sites) would be fivefold higher for the 
decamer. However, it must also be considered that sterics or a 
high formal negative charge may impede immobilization of 
similar numbers of the larger sPRP oligosaccharides. Similar 
binding levels observed for all sPRP oligosaccharides to the 
rabbit serum at low dilutions (Figure 4b) are not necessarily an 
indication of similar epitope densities, as different antibodies 
react differently to changes in epitope density on glycan 
arrays30 and crowding effects at high antibody concentrations 
might outweigh the advantages of having high epitope 
densities. There are more pronounced differences in 
fluorescence intensity at higher dilutions for the rabbit typing 
serum, as can clearly be seen in the lowest PRP concentration 
point in Figure 4d. 
 
Conjugation of CRM197 to sPRP oligosaccharides 1, 2, 3, and 4 
After establishing the immunological cross-reactivity of the 
sPRP constructs with PRP-directed antibodies, immunization 
studies with sPRP-CRM197 glycoconjugates were initiated. 
Mindful of the fact that proper conjugation chemistry is key to 
efficient glycoconjugate production,31 and the importance of 
choosing a linker that induces minimal undesired immunogenic 
responses,32 the well-established thiol-maleimide coupling 
method was chosen17,24,33,34 The sPRP oligosaccharides were 
conjugated to CRM197, a carrier protein that has been 
successfully used in commercial vaccines and immunological 
studies in conjunction with a variety of antigens.17,24,33,34 The 
amine group of the linker of sPRP oligosaccharide 1 was reacted 
with commercially available dithiobis(succinimidylpropionate) 
(DSP) in phosphate buffer (pH 7.4) at room temperature 
(Scheme 5). The disulfide bond was then cleaved using 
dithiothreitol (DTT) at room temperature to obtain the thiol 
products. Cleavage was confirmed by 1H NMR and MALDI-TOF 
MS (Supplementary Information). The same procedure was 
applied to sPRP oligosaccharides 2-4. To obtain maleimide-
containing CRM197, the protein was incubated with N-
succinimidyl 3-maleimidopropionate (SMP) in phosphate 
buffer, pH 7.4, at room temperature for 2 h (Scheme 5). The 
average stoichiometry of maleimide linkers covalently attached 
to the protein was determined by MALDI-TOF MS to be 10.4 
(Supplementary Information).  
The well-defined thiol modified sPRP oligosaccharides were 
conjugated to the maleimide-containing CRM197 in phosphate 
buffer (pH 7.4) at room temperature (Scheme 5) to afford 
Scheme 5. Conjugation of sPRP oligosaccharides 1-4 to CRM197 via the corresponding thiols. x represents the protein loading stoichiometry. 
Average loading values are 4.9 (for 1), 4.0 (for 2), 3.1 (for 3), and 2.7 (for 4). 
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glycoconjugates 1-CRM197, 2-CRM197, 3-CRM197 and 4-
CRM197. The number of sPRP oligosaccharides conjugated to 
CRM197 in each case was calculated from the mass shift 
measured using MALDI-TOF MS (Supplementary Information 
Table S1). Further characterization of the glycoconjugates was 
performed using SDS-polyacrylamide gel electrophoresis (SDS-
PAGE) confirming an increase in molecular weight; Western blot 
with polyclonal anti-diphtheria toxin reactive to CRM197 as 
positive control and anti-Hib antibodies showed specific 
attachment of Hib-reactive epitopes for all conjugates. PRP 
content determination based on high performance anion 
exchange chromatography with pulsed amperometric detection 
after alkaline hydrolysis (HPAEC-PAD) was used to confirm the 
loading from MALDI (Figure S2).35 The HPAEC-PAD data was in 
good agreement with MALDI-MS for conjugates 1-CRM197 
through 3-CRM197; however, the observed saccharide 
concentration for 4-CRM197 was significantly lower than 
expected based on the MS data (Supplementary Information 
Figure S3 and Table S1). 
 
Immunogenicity studies in rabbits 
The sPRP-CRM197 glycoconjugates were used to immunize Zika 
rabbits, the animal model of choice in earlier immunization 
studies involving sPRP oligosaccharides.16,20 Six groups with four 
rabbits per group were immunized in a prime-boost regime with 
unadjuvanted glycoconjugate containing 5 µg sPRP per 
immunization (Figure 5a). The negative control group received 
CRM197, and the positive control group the approved vaccine 
ActHIB (5 µg PRP, corresponding to half the human dose), a 
conjugate of native PRP to TT.36 
Serum IgG levels on day 35, one week after the second 
boost, towards the sPRP oligosaccharides were determined by 
glycan array analysis (Figures 5 and S4). As expected, no binding 
to the oligosaccharides was observed for the CRM197-
immunized negative control group, confirming that the 
antibody response originates from the oligosaccharide 
component of the conjugate. The sPRP conjugates showed 
different levels of immunogenicity without a clear length-
dependent trend, as tetramer conjugate 1-CRM197 and 
octamer conjugate 3-CRM197 exhibited the highest 
immunogenicities. This indicates that an RU tetramer is 
sufficient for optimal immunogenicity, in agreement with an 
earlier investigation of an sPRP tetramer-TT conjugate that 
elicited antibody levels in monkeys similar to those of a CRM197 
conjugate of size-reduced PRP with an average of 20 repeating 
units.10 Comparatively lower elicited antibody levels were 
observed for hexamer conjugate 2-CRM197 and decamer 
conjugate 4-CRM197. In the latter case, the low 
immunogenicity may be caused by a too low oligosaccharide 
dose used for immunization (see above). However, IgM levels in 
rabbits immunized with 4-CRM197 were more similar to those 
elicited by 1-CRM197 and 3-CRM197 suggesting that the 
amount of carbohydrate was sufficient for a comparable 
immune response (Supplementary Figure S5) We are confident 
based on the characterization data that the hexamer conjugate 
2-CRM197 preparation is of similar quality to the more 
immunogenic 1-CRM197 and 3-CRM197 samples, and that the 
lower immunogenicity is therefore an intrinsic feature of the RU 
hexamer. PRP is believed to form highly ordered, rigid 
secondary structures,37 and, depending on the available 
number of repeating units, oligosaccharides might fold into 
structures that interact with immune receptors in different 
Figure 5: Immunization of rabbits with sPRP glycoconjugates, CRM197 negative 
control and ActHIB positive control. (a) Prime-boost immunization regime. 
Each dose contained 5 µg PRP. (b) IgG response to Hib RU dimer S4 as 
determined by glycan array. Bar chart (left): response measured with serum 
diluted 1:40. Line plot (right): dilution-response series. (c) IgG response 
towards Hib RU decamer 4 as determined by glycan array. Charts as in (b). See 
Supplementary Information Figure S4 a-c for antibody response toward 1-3 as 
determined by glycan array. (d) IgG response towards native Hib PRP measured 
by ELISA. Bar chart (left): response measured with serum diluted 1:270. Line 
plot (right): dilution-response series (b-d) Each data point represents the mean 
of four animals with error bars representing the standard error of the mean 
(SEM). 
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ways. These immune receptors not only include B cell receptors 
and antibodies, but also other cell surface receptors such as 
lectins whose engagement by oligo- and polysaccharides can 
intensify or attenuate an immune response.38 This more 
complex in vivo setting explains the apparent discrepancy with 
the glycan array serum analysis (Figure 4) that showed more 
uniform results. 
Similar to our observations, it was previously shown that 
penta- and hexamers linked to synthetic T cell epitopes were of 
lower immunogenicity than a trimer.20 This conformational 
influence may also extend to the decamer (as mentioned above, 
a comparatively strong IgM response was induced here). It is 
also possible that the penta- and hexamers were too large for 
efficient processing of the T cell antigens. Rabbits, used as the 
animal model in our as well as the previous studies, may 
contribute to the lower immunogenicity seen for single 
construct because they are not inbred and have more variable 
experimental outcomes than mice.39 However, mice are an 
unreliable animal model for sPRP conjugates.16,20 
For a vaccine, the important measure is not reactivity to the 
synthetic oligosaccharides but serum reactivity towards the 
capsule which is often measured by IgG towards the natural 
PRP.16,17,20 The differences in immunogenicity seen in the 
response to the sPRP oligosaccharides on glycan arrays, namely 
high IgG levels in the cases of 1-CRM197 and 3-CRM197 and low 
in the cases of 2-CRM197 and 4-CRM197, were clearly mirrored 
when an enzyme-linked immunosorbent assay (ELISA) was used 
to determine the IgG binding levels towards native PRP (Figure 
5d). The responses are similar between 1-CRM197 and 3-
CRM197, suggesting that RU tetramer 1 is not only as 
immunogenic as the larger oligosaccharides but also is able to 
induce the production of antibodies with a similar degree of 
cross-reactivity.  
Immunogenicity of the positive control ActHIB is higher than 
that of the sPRP conjugates and may be attributed to the 
different carrier protein, as higher titers have previously been 
obtained in rabbits for sPRPs conjugated to TT compared to 
CRM197.16 Likely, this is a rabbit specific effect as the carrier 
proteins do not differ significantly in inducing immune 
responses in human Hib vaccines based on isolated PRP. 40 
However, possible differences between carrier proteins in 
humans have not yet been evaluated for sPRPs. 
Conclusions 
Quimi-Hib, the only marketed sPRP glycoconjugate vaccine, 
contains a mixture of different length oligosaccharides.17 With 
the goal of understanding the effect of glycotope length on 
vaccine design, access to well-defined Hib oligosaccharides is 
crucial for providing the necessary tools for in-depth 
immunological evaluations. We developed a strategy for the 
[2+2], [4+2], [6+2], and [8+2] syntheses of sPRP oligosaccharides 
using orthogonal protecting groups. The synthetic route 
described here improved upon the existing methods for 
preparing the key ribitol and ribose-ribitol intermediates, and a 
one-pot coupling and cleavage process significantly simplified 
the purification process and improved yields. The sPRP 
oligosaccharides are similar to natural Hib PRP, as is evident 
from the NMR and biological data. Glycan array analyses 
revealed that sPRP oligosaccharides present cross-reactive 
epitopes to antibodies raised against isolated PRP. 
Glycoconjugates of sPRP oligosaccharides are immunogenic in a 
rabbit model, whereby tetrameric sPRP 1 is an excellent starting 
point for the design of a defined semi-synthetic glycoconjugate 
Hib vaccine.  
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